Makes heparin products, from crude heparin and heparin-sodium raw material to enoxaparin and other low-molecular-weight heparin injections.
Makes heparin products, from crude heparin and heparin-sodium raw material to enoxaparin and other low-molecular-weight heparin injections.
Sells heparin, an anticoagulant drawn from pig intestines, in raw and finished forms: crude heparin, pharmaceutical-grade active ingredient, and low-molecular-weight heparin injections such as enoxaparin and dalteparin. Raw material and injections are the main income sources, with exports to Europe and the US a stated growth push and hospital sales set by China's bulk-purchase tenders.
Moat: narrow (regulatory licence, customer qualification). Holds several LMWH approvals and EU GMP certification for enoxaparin and heparin raw materials.
Headquarters: Shijiazhuang, China · Founded: 2000 · Employees: 1,194
Size Hebei Changshan Biochemical Pharmaceutical (300255.SZ) is a China Health Care company (Biotechnology) with a market value of $2.33B, the 1034th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.22 on 18 Nov 2026.
Performance Over six months the shares fell 58.9%, against -10.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 0.2% over the last twelve months (peer median +10.7%); the operating margin is -25.4% (peer median -13.6%).
Valuation It trades at 19.4× enterprise value to sales against a peer median of 9.4× (5th most expensive of 16).
Capital Return on invested capital runs 12.5 points below its cost of capital (8.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥930M | CN¥874M | CN¥1.03B | CN¥1.40B | CN¥2.32B |
| Revenue growth | — | -15% | -26% | -40% | — |
| Gross profit | CN¥221M | CN¥104M | CN¥137M | CN¥277M | CN¥1.00B |
| EBITDA | n/a | -CN¥192M | -CN¥128M | -CN¥1.08B | CN¥162M |
| Net income | -CN¥351M | -CN¥358M | -CN¥249M | -CN¥1.24B | CN¥17.5M |
| Free cash flow | -CN¥181M | -CN¥71.7M | -CN¥191M | -CN¥206M | -CN¥428M |
| Capital expenditure | CN¥131M | CN¥123M | CN¥240M | CN¥239M | CN¥431M |
| Total debt | CN¥2.61B | CN¥2.63B | CN¥2.58B | CN¥2.37B | CN¥2.53B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | $2.33B | -59% | 0% | -25% | 19.4× | n/a |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | $1.80B | -12% | -6% | 8% | 2.1× | -0.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | $2.03B | -3% | +9% | 14% | 3.2× | 5.1% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300255.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.5% | -7.4% | 7th lowest of 21 |
| 6-month return | -58.9% | -10.8% | lowest of 20 |
| Distance from 52-week high | -75.4% | -35.0% | lowest of 21 |
| Revenue growth (TTM) | +0.2% | +10.7% | 7th lowest of 18 |
| Operating margin | -25.4% | -13.6% | 7th lowest of 16 |
| EV / Sales | 19.4× | 9.4× | 5th most expensive of 16 |
| ROIC minus cost of capital | -12.5 pp | -6.1 pp | 4th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | 38.7× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | 5.9× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |